Table 2. Meta-analysis of the association between the NFKB1 -94ins/delATTG (rs28362491) polymorphism and overall cancer risk.
| Variables | No. of studies | Sample size | Homozygous | Heterozygous | Recessive | Dominant | Allele | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DD vs. II | ID vs. II | DD vs. ID/II | ID/DD vs. II | D vs. I | ||||||||
| OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | |||
| All | 50 | 18299/ 23484 | 0.75 (0.64-0.87) | <0.001 | 0.91 (0.83-0.99) | <0.001 | 0.81 (0.71-0.91) | <0.001 | 0.86 (0.78-0.95) | <0.001 | 0.88 (0.81-0.95) | <0.001 |
| Cancer type | ||||||||||||
| HCC | 6 | 1471/ 3390 | 0.65 (0.38-1.11) | <0.001 | 0.82 (0.56-1.19) | <0.001 | 0.74 (0.54-1.02) | 0.006 | 0.75 (0.50-1.15) | <0.001 | 0.80 (0.61-1.07) | <0.001 |
| Lung | 5 | 2793/ 2921 | 0.77 (0.48-1.26) | <0.001 | 0.84 (0.74-0.96) | 0.337 | 0.82 (0.54-1.26) | <0.001 | 0.83 (0.67-1.03) | 0.012 | 0.88 (0.70-1.09) | <0.001 |
| Colorectal | 4 | 2399/ 3653 | 0.96 (0.65-1.43) | 0.001 | 1.08 (0.79-1.47) | <0.001 | 0.92 (0.69-1.22) | 0.022 | 1.05 (0.77-1.44) | <0.001 | 1.01 (0.82-1.24) | <0.001 |
| NPC | 4 | 2053/ 2482 | 0.66 (0.56-0.78) | 0.467 | 0.85 (0.75-0.97) | 0.537 | 0.73 (0.63-0.85) | 0.755 | 0.79 (0.69-0.90) | 0.371 | 0.81 (0.74-0.89) | 0.316 |
| Prostate | 4 | 1930/ 2166 | 0.59 (0.48-0.72) | 0.684 | 0.74 (0.62-0.88) | 0.803 | 0.77 (0.65-0.92) | 0.267 | 0.69 (0.59-0.81) | 0.760 | 0.79 (0.72-0.87) | 0.540 |
| Ovarian | 4 | 1463/ 1573 | 0.54 (0.40-0.73) | 0.173 | 0.73 (0.61-0.87) | 0.416 | 0.68 (0.52-0.89) | 0.102 | 0.67 (0.56-0.79) | 0.462 | 0.75 (0.65-0.86) | 0.181 |
| Bladder | 3 | 1058/ 1175 | 0.93 (0.40-2.21) | <0.001 | 0.95 (0.74-1.22) | 0.193 | 0.97 (0.43-2.17) | <0.001 | 0.96 (0.67-1.37) | 0.026 | 0.97 (0.66-1.43) | <0.001 |
| Gastric | 3 | 1062/ 1429 | 0.97 (0.41-2.31) | <0.001 | 0.88 (0.60-1.30) | 0.032 | 1.11 (0.57-2.15) | <0.001 | 0.90 (0.54-1.49) | 0.002 | 0.98 (0.65-1.50) | <0.001 |
| Cervical | 3 | 573/ 755 | 0.41 (0.15-1.11) | 0.001 | 0.85 (0.67-1.08) | 0.627 | 0.44 (0.17-1.12) | 0.001 | 0.69 (0.45-1.04) | 0.050 | 0.66 (0.39-1.10) | <0.001 |
| OSCC | 2 | 674/ 721 | 0.49 (0.33-0.72) | 0.222 | 0.67 (0.51-0.88) | 0.570 | 0.63 (0.49-0.81) | 0.308 | 0.60 (0.46-0.77) | 0.377 | 0.70 (0.60-0.82) | 0.300 |
| Breast | 2 | 710/ 704 | 0.92 (0.13-6.42) | <0.001 | 1.13 (0.51-2.54) | 0.002 | 0.85 (0.20-3.61) | <0.001 | 1.13 (0.38-3.37) | <0.001 | 1.04 (0.43-2.53) | <0.001 |
| Others | 10 | 2113/ 4263 | 1.07 (0.88-1.31) | 0.281 | 1.16 (0.94-1.42) | 0.006 | 1.00 (0.86-1.16) | 0.483 | 1.14 (0.94-1.38) | 0.008 | 1.06 (0.95-1.19) | 0.062 |
| Ethnicity | ||||||||||||
| Asians | 38 | 15079/ 18673 | 0.67 (0.55-0.80) | <0.001 | 0.86 (0.79-0.94) | <0.001 | 0.75 (0.65-0.86) | <0.001 | 0.80 (0.72-0.89) | <0.001 | 0.83 (0.76-0.91) | <0.001 |
| Chinese | 34 | 13834/ 16989 | 0.68 (0.56-0.81) | <0.001 | 0.84 (0.77-0.93) | <0.001 | 0.77 (0.67-0.88) | <0.001 | 0.80 (0.71-0.89) | <0.001 | 0.84 (0.76-0.91) | <0.001 |
| Caucasians | 12 | 3220/ 6559 | 1.08 (0.92-1.27) | 0.221 | 1.11 (0.94-1.30) | 0.004 | 1.02 (0.88-1.17) | 0.269 | 1.10 (0.95-1.28) | 0.010 | 1.06 (0.98-1.15) | 0.141 |
| Source of control | ||||||||||||
| HB | 40 | 12614/ 15682 | 0.70 (0.58-0.85) | <0.001 | 0.88 (0.80-0.98) | <0.001 | 0.76 (0.65-0.89) | <0.001 | 0.84 (0.74-0.94) | <0.001 | 0.85 (0.77-0.94) | <0.001 |
| PB | 10 | 5685/ 9550 | 0.95 (0.79-1.15) | 0.001 | 1.00 (0.86-1.15) | 0.002 | 0.98 (0.88-1.09) | 0.161 | 0.98 (0.84-1.14) | <0.001 | 0.98 (0.90-1.08) | <0.001 |
| Quality score | ||||||||||||
| >9 | 19 | 9894/ 13117 | 0.87 (0.73-1.04) | <0.001 | 0.93 (0.84-1.04) | <0.001 | 0.92 (0.80-1.05) | <0.001 | 0.91 (0.81-1.03) | <0.001 | 0.94 (0.86-1.02) | <0.001 |
| ≤9 | 31 | 8405/ 12115 | 0.68 (0.53-0.86) | <0.001 | 0.89 (0.79-1.01) | <0.001 | 0.73 (0.60-0.88) | <0.001 | 0.83 (0.71-0.96) | <0.001 | 0.84 (0.75-0.95) | <0.001 |
Het, heterogeneity; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; OSCC, oral squamous cell carcinoma; HB, hospital-based; PB, population-based.